Neoadjuvant lenvatinib in a patient with invasive poorly differentiated thyroid cancer
Neadjuvant lenvatinib can be a therapeutic option to reduce primary tumour extent, in order to perform surgery and achieve better outcomes. However, this requires a highly selected patient group. Neoadjuvant-targeted therapy holds significant promise and warrants further investigation.
Authors
- Fernando Carrizo
- Inés Califano (ORCID: https://orcid.org/0000-0002-7450-5832)
- Sergio Quildrian (ORCID: https://orcid.org/0000-0001-5794-7084)
- Santiago Zund
Institutions
- Twitter (United States) (US)
- Instituto Cardiovascular de Buenos Aires (AR)
Publication Details
- Journal
- ecancermedicalscience
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3332/ecancer.2025.1902
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29